RecruitingPhase 1NCT07219368

A First-in-Human Single and Multiple Ascending Dose Study of MT-201

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Doses of MT-201 in Healthy Participants

Sponsor

Mirador Therapeutics, Inc.

Enrollment

72 participants

Start Date

Oct 8, 2025

Study Type

INTERVENTIONAL

Conditions

Healthy Volunteer

Summary

First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-201 in healthy participants.

Eligibility

Min Age: 19 YearsMax Age: 55 Years

Inclusion Criteria5

Male participant or female participant of nonchildbearing potential between 19 and 55 years of age (inclusive) at the time of signing informed consent.
Female participants must be of nonchildbearing potential, defined as postmenopausal or surgically sterile, and have official documentation, at least 6 months prior to the first dose.
Male participants with female partners of childbearing potential who are involved in heterosexual intercourse or activities that could lead to pregnancy must use barrier method of contraception (male condom) and refrain from sperm donation.
Good general health.
Able to provide written informed consent and understand and comply with the requirements of the study.

Exclusion Criteria6

History or presence of any clinically significant organ system disease.
Abnormal laboratory assessments, physical exam of ECG outside the normal range that is judged by the Investigator to be clinically significant.
History of alcohol or drug abuse within the past 24 months.
Current use or history of regular tobacco, or nicotine-containing products within 3 months prior to screening.
Administration or use of any investigational drug or device within 30 days preceding the first dose of study drug administration.
Blood donation within 60 days prior to dosing or plasma donation within 14 days prior to dosing.